In an ESMO expert interview, D. Arnold elaborates the prognostic value of Immunoscore in stage I-III colon cancer and the results of phase II study of nivolumab in refractory anal cancer, as presented at ASCO 2016 Annual Meeting. He says that he will be surprised if checkpoint inhibitors don’t find place soon in therapeutic algorithm of gastrointestinal malignancies.